In NSCLC, the tyrosine kinase domain-encoding portion of MET creates a fusion gene with a wide variety of partners [48], including TPR, KIF5B, HLA-DRB1 [49,50,51], making the receptor constitutively activated. The gene discussed is MET; the disease is non-small cell lung carcinoma.